The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Diversity in specificity, abundance, and composition of anti-Neu5Gc antibodies in normal humans: Potential implications for disease
Open accessAbstract
Human heterophile antibodies that agglutinate animal erythrocytes are known to detect the nonhuman sialic acid N-glycolylneuraminic acid (Neu5Gc). This monosaccharide cannot by itself fill the binding site (paratope) of an antibody and can also be modified and presented in various linkages, on diverse underlying glycans. Thus, we hypothesized that the human anti-Neu5Gc antibody response is diverse and polyclonal. Here, we use a novel set of natural and chemoenzymatically synthesized glycans to show that normal humans have an abundant and diverse spectrum of such anti-Neu5Gc antibodies, directed against a variety of Neu5Gc-containing epitopes. High sensitivity and specificity assays were achieved by using N-acetylneuraminic acid (Neu5Ac)-containing probes (differing from Neu5Gc by one less oxygen atom) as optimal background controls. The commonest anti-Neu5Gc antibodies are of the IgG class. Moreover, the range of reactivity and Ig classes of antibodies vary greatly amongst normal humans, with some individuals having remarkably large amounts, even surpassing levels of some well-known natural blood group and xenoreactive antibodies. We purified these anti-Neu5Gc antibodies from individual human sera using a newly developed affinity method and showed that they bind to wild-type but not Neu5Gc-deficient mouse tissues. Moreover, they bind back to human carcinomas that have accumulated Neu5Gc in vivo. As dietary Neu5Gc is primarily found in red meat and milk products, we suggest that this ongoing antigen-antibody reaction may generate chronic inflammation, possibly contributing to the high frequency of diet-related carcinomas and other diseases in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Paradoxical roles of the immune system during cancer development
de Visser, K. E., Eichten, A., & Coussens, L. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1782 · Cited by 2,256
Clinical and Experimental Immunology
Kay, H. (1966) · PubMed Central · Cited by 2,177
Biomarkers in Cancer Staging, Prognosis and Treatment Selection
Ludwig, J. A., & Weinstein, J. N. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1739 · Cited by 1,666
Chemical Diversity in the Sialic Acids and Related α-Keto Acids: An Evolutionary Perspective
Angata, T., & Varki, A. (2002) · Chemical Reviews · doi:10.1021/cr000407m · Cited by 1,237
Self-citationHuman uptake and incorporation of an immunogenic nonhuman dietary sialic acid
Tangvoranuntakul, P., Gagneux, P., Diaz, S., Bardor, M., Varki, N., Varki, A., & Muchmore, E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2131556100 · Cited by 625
Self-citationGalili, U., Mandrell, R. E., Hamadeh, R. M., Shohet, S. B., & Griffiss, J. M. (1988) · Infection and Immunity · doi:10.1128/iai.56.7.1730-1737.1988 · Cited by 548
Rose, D. P., Boyar, A. P., & Wynder, E. L. (1986) · Cancer · doi:10.1002/1097-0142(19861201)58:11<2363::aid-cncr2820581102>3.0.co;2-# · Cited by 518
Mucin‐type O ‐glycans in human colon and breast cancer: glycodynamics and functions
Brockhausen, I. (2006) · EMBO reports · doi:10.1038/sj.embor.7400705 · Cited by 511
Meat consumption and colorectal cancer risk: Dose‐response meta‐analysis of epidemiological studies
Norat, T., Lukanova, A., Ferrari, P., & Riboli, E. (2002) · International Journal of Cancer · doi:10.1002/ijc.10126 · Cited by 501
Key, T. J., Fraser, G. E., Thorogood, M., Appleby, P. N., Beral, V., Reeves, G., Burr, M. L., Chang-Claude, J., Frentzel-Beyme, R., Kuzma, J. W., et al. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/70.3.516s · Cited by 484
Cited by
Glycosylation as a strategy to improve antibody-based therapeutics
Jefferis, R. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2804 · Cited by 829
“Similarly, CHO, NS0 and Sp2/0 cells can add an α(2–3)-linked N -glycylneuraminic acid that is not present in humans and that might also be immunogeni”
BackgroundMammalian glycosylation in immunity
Marth, J. D., & Grewal, P. K. (2008) · Nature Reviews Immunology · doi:10.1038/nri2417 · Cited by 712
Sialic acids as regulators of molecular and cellular interactions
Schauer, R. (2009) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2009.06.003 · Cited by 673
Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives
Dumont, J., Euwart, D., Mei, B., Estes, S., & Kshirsagar, R. (2016) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2015.1084266 · Cited by 483
Liu, L. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24444 · Cited by 428
A red meat-derived glycan promotes inflammation and cancer progression
Samraj, A. N., Pearce, O. M. T., Läubli, H., Crittenden, A. N., Bergfeld, A. K., Banda, K., Gregg, C. J., Bingman, A. E., Secrest, P., Diaz, S. L., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1417508112 · Cited by 407
Self-citationFc glycans of therapeutic antibodies as critical quality attributes
Reusch, D., & Tejada, M. L. (2015) · Glycobiology · doi:10.1093/glycob/cwv065 · Cited by 404
Expression systems for therapeutic glycoprotein production
Durocher, Y., & Butler, M. (2009) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2009.10.008 · Cited by 386
Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins
Ghaderi, D., Taylor, R. E., Padler-Karavani, V., Diaz, S., & Varki, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1651 · Cited by 372
Self-citationGhaderi, D., Zhang, M., Hurtado-Ziola, N., & Varki, A. (2012) · Biotechnology and Genetic Engineering Reviews · doi:10.5661/bger-28-147 · Cited by 320
Self-citationTherapeutic glycoprotein production in mammalian cells
Lalonde, M.-E., & Durocher, Y. (2017) · Journal of Biotechnology · doi:10.1016/j.jbiotec.2017.04.028 · Cited by 296
“Murine cells can also produce α-gal and Neu5Gc at considerably higher levels than hamster cells, increasing the risks of immunogenicity (Tangvoranuntakul et al., 2003; Chung et al., 2008; Macher and Galili, 2008; Padler-Karavani et al., 2008; Ghaderi et al., 2012).”
BackgroundSialic acid metabolism and sialyltransferases: natural functions and applications
Li, Y., & Chen, X. (2012) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-012-4040-1 · Cited by 281
Self-citationFc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics
Rath, T., Baker, K., Dumont, J. A., Peters, R. T., Jiang, H., Qiao, S.-W., Lencer, W. I., Pierce, G. F., & Blumberg, R. S. (2015) · Critical Reviews in Biotechnology · doi:10.3109/07388551.2013.834293 · Cited by 281
Glycobiology of immune responses
Rabinovich, G. A., van Kooyk, Y., & Cobb, B. A. (2012) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06492.x · Cited by 279
Uniquely human evolution of sialic acid genetics and biology
Varki, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914634107 · Cited by 278
Self-citationAggregation of Protein Therapeutics Enhances Their Immunogenicity: Causes and Mitigation Strategies
Lundahl, M. L. E., Fogli, S., Colavita, P. E., & Scanlan, E. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00067e · Cited by 212
Involvement of a Non-Human Sialic Acid in Human Cancer
Samraj, A. N., Läubli, H., Varki, N., & Varki, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00033 · Cited by 196
Self-citationSugar‐coated sperm: Unraveling the functions of the mammalian sperm glycocalyx
Tecle, E., & Gagneux, P. (2015) · Molecular Reproduction and Development · doi:10.1002/mrd.22500 · Cited by 190
“As a consequence, humans make antibodies against Neu5Gc when exposed to this molecule in red meat and cow dairy products (Padler-Karavani et al., 2008; Taylor et al., 2010).”
BackgroundHuman cells: new platform for recombinant therapeutic protein production
Swiech, K., Picanço-Castro, V., & Covas, D. T. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.04.023 · Cited by 178
Potential impact of the non‐human sialic acid N‐glycolylneuraminic acid on transplant rejection risk
Padler‐Karavani, V., & Varki, A. (2011) · Xenotransplantation · doi:10.1111/j.1399-3089.2011.00622.x · Cited by 162
Self-citationAlisson-Silva, F., Kawanishi, K., & Varki, A. (2016) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.07.002 · Cited by 156
Self-citationAbsence of Neu5Gc and Presence of Anti-Neu5Gc Antibodies in Humans—An Evolutionary Perspective
Altman, M. O., & Gagneux, P. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00789 · Cited by 112
Potential deleterious role of anti‐Neu5Gc antibodies in xenotransplantation
Salama, A., Evanno, G., Harb, J., & Soulillou, J. (2015) · Xenotransplantation · doi:10.1111/xen.12142 · Cited by 81
Characterization of immunogenic Neu5Gc in bioprosthetic heart valves
Reuven, E. M., Leviatan Ben‐Arye, S., Marshanski, T., Breimer, M. E., Yu, H., Fellah‐Hebia, I., Roussel, J., Costa, C., Galiñanes, M., Mañez, R., et al. (2016) · Xenotransplantation · doi:10.1111/xen.12260 · Cited by 80
Self-citationSexual selection by female immunity against paternal antigens can fix loss of function alleles
Ghaderi, D., Springer, S. A., Ma, F., Cohen, M., Secrest, P., Taylor, R. E., Varki, A., & Gagneux, P. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1102302108 · Cited by 79
Self-citationGlycosylated Biotherapeutics: Immunological Effects of N-Glycolylneuraminic Acid
Yehuda, S., & Padler-Karavani, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00021 · Cited by 71
Self-citationGlycoengineering in CHO cells: advances in systems biology
Tejwani, V., Andersen, M. R., Nam, J. H., & Sharfstein, S. T. (2018) · Biotechnology Journal · doi:10.1002/biot.201700234 · Cited by 70
Glycosylation shapes the efficacy and safety of diverse protein, gene and cell therapies
Rocamora, F., Peralta, A. G., Shin, S., Sorrentino, J., Wu, M. Y. M., Toth, E. A., Fuerst, T. R., & Lewis, N. E. (2023) · Biotechnology Advances · doi:10.1016/j.biotechadv.2023.108206 · Cited by 67
The Possible Role of Anti-Neu5Gc as an Obstacle in Xenotransplantation
Tector, A. J., Mosser, M., Tector, M., & Bach, J.-M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00622 · Cited by 60
Anti-Neu5Gc and anti-non-Neu5Gc antibodies in healthy humans
Gao, B., Long, C., Lee, W., Zhang, Z., Gao, X., Landsittel, D., Ezzelarab, M., Ayares, D., Huang, Y., Cooper, D. K. C., et al. (2017) · PLOS ONE · doi:10.1371/journal.pone.0180768 · Cited by 58
Blondeel, E. J. M., & Aucoin, M. G. (2018) · Biotechnology Advances · doi:10.1016/j.biotechadv.2018.06.008 · Cited by 46
Natural Antibodies Against Sialoglycans
Shilova, N., Huflejt, M. E., Vuskovic, M., Obukhova, P., Navakouski, M., Khasbiullina, N., Pazynina, G., Galanina, O., Bazhenov, A., & Bovin, N. (2013) · Topics in Current Chemistry · doi:10.1007/128_2013_469 · Cited by 22
“There are many reports on the presence of antibodies against Neu5Gc in form of HD-antigen, with 2-3 bound glycolylneuraminic acid, Neu5Gcα2-3Galβ1-4Glc or Neu5Gcα2-3Galβ1-4GlcNAc [25, 26] in humans.”
Background
Metadata
- Authors
- Padler-Karavani, V., Yu, H., Cao, H., Chokhawala, H., Karp, F., Varki, N., Chen, X., & Varki, A.
- Venue
- Glycobiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-06-06
- Volume
- 18
- Issue
- 10
- Pages
- 818-830
- ISSN
- 0959-6658 (ISSN-L)
- 1460-2423
- OpenAlex
- W2153180588
- Cited by
- 326
- References
- 59
- FWCI
- 5.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.